OSLO,
Norway, May 18, 2022 /PRNewswire/
-- Photocure ASA (OSE: PHO), the Bladder Cancer Company,
announces the conclusion of a productive AUA 2022 Conference: the
American Urological Association Annual Congress 2022, an in-person
event for the first time since 2019, was held May 13-16, 2022 in New
Orleans, LA, USA. Both the Photocure and Karl Storz exhibit
booths provided information to AUA attendees on the New Blue Light
equipment, for which interest was strong. During the program, a
poster by Dr. Sia Daneshmand was
presented on restaging TURBTs in NMIBC* featuring Photocure's
Cysview® product.
The American Urological Association (AUA) meeting is one of
largest international meetings in the urology calendar. The yearly
event includes an innovative, evidence-based, quality program
for urologists and urologic health care professionals
worldwide.
The New Blue Light equipment from Karl Storz was prominently
displayed on the exhibition floor, as urologists visited both the
Photocure and Karl Storz booths to inquire about the New Blue Light
System, the next generation equipment in bladder cancer detection.
The Karl Storz equipment is the only FDA approved device for BLC
with Cysview in the U.S. Physicians were able to get hands on
experience with the new system at the Karl Storz booth.
"We have been working closely with Karl Storz for several
months to support a successful launch of the New Blue Light system
and were very pleased with the interest expressed among
uro-oncologists who visited our booth on the exhibition floor. We
were able to share some of the key features and benefits of The New
Blue Light and liaised with the Karl Storz team for firsthand
demonstrations. Given the positive feedback during AUA, we
anticipate that several launch events will support the education
and practice needs for the urology community. Additionally,
Photocure prominently displayed the Flexible BLC system at its
booth. The positive feedback from uro-oncologists further
reinforces the recent surge in flexible blue light tower
installations and how outpatient surveillance with flexible BLC
helps support the continuum of care for patients with bladder
cancer." said Geoff Coy, Vice
President & General Manager North
America.
This year's AUA program also once again featured NMIBC topics
including Blue Light Cystoscopy. A poster from Dr. Sia Daneshmand was presented entitled "Is a
Restaging TURBT** Necessary in Non-Muscle Invasive Bladder Cancer
if the Initial TURBT was Performed Using Blue Light?" This podium
poster presentation highlighted that patients who underwent BLC for
their initial TURBT had more benign pathology upon a restaging
TURBT compared to WLC, though a restaging TURBT is still advised.
Dr. Sia Daneshmand, M.D., is
Professor of Urology with Clinical Scholar designation and serves
as director of clinical research as well as the urologic oncology
(SUO) fellowship director at the University of
Southern California (USC) in
Los Angeles.
Read the abstract here:
https://www.eventscribe.net/2022/AUA2022/fsPopup.asp?Mode=presInfo&PresentationID=1051890
*NMIBC: Non-muscle invasive bladder cancer
**TURBT: Transurethral resection of bladder tumo
Note to editors:
All trademarks mentioned in this release are protected by law
and are registered trademarks of Photocure ASA
About Bladder Cancer
Bladder cancer ranks as the 8th most common cancer
worldwide – the 5th most common in men – with
1 720 000 prevalent cases (5-year prevalence
rate)1a, 573 000 new cases and more than
200 000 deaths in 2020.1b
Approx. 75% of all bladder cancer cases occur in
men.1 It has a high recurrence rate with up to 61% in
year one and up to 78% over five years.2 Bladder cancer
has the highest lifetime treatment costs per patient of all
cancers.3
Bladder cancer is a costly, potentially progressive disease for
which patients have to undergo multiple cystoscopies due to the
high risk of recurrence. There is an urgent need to improve both
the diagnosis and the management of bladder cancer for the benefit
of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive
bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC),
depending on the depth of invasion in the bladder wall. NMIBC
remains in the inner layer of cells lining the bladder. These
cancers are the most common (75%) of all BC cases and include the
subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the
cancer has grown into deeper layers of the bladder wall. These
cancers, including subtypes T2, T3 and T4, are more likely to
spread and are harder to treat.4
1 Globocan. a) 5-year prevalence / b)
incidence/mortality by population. Available at:
https://gco.iarc.fr/today, accessed [January
2022].
2 Babjuk M, et al. Eur Urol. 2019; 76(5):
639-657
3 Sievert KD et al. World J Urol
2009;27:295–300
4 Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html
About
Hexvix®/Cysview® (hexaminolevulinate
HCl)
Hexvix/Cysview is a drug that preferentially accumulates in
cancer cells in the bladder, making them glow bright pink during
Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview,
compared to standard white light cystoscopy alone, improves the
detection of tumors and leads to more complete resection, fewer
residual tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all
other markets. Photocure is commercializing Cysview/Hexvix directly
in the U.S. and Europe and has
strategic partnerships for the commercialization of Hexvix/Cysview
in China, Chile, Australia, and New
Zealand. Please refer to
https://photocure.com/partners/our-partners for further information
on our commercial partners.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative
solutions to improve the lives of bladder cancer patients. Our
unique technology, making cancer cells glow bright pink, has led to
better health outcomes for patients worldwide. Photocure is
headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information,
please visit us at www.photocure.com, www.hexvix.com,
www.cysview.com
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/photocure/r/blue-light-cystoscopy-continues-to-make-news-at-aua-2022,c3569156
The following files are available for download:
|
https://mb.cision.com/Main/17498/3569156/1581045.pdf
|
Release
|
View original
content:https://www.prnewswire.com/news-releases/blue-light-cystoscopy-continues-to-make-news-at-aua-2022-301549814.html
SOURCE Photocure